肺癌领域ADC药物掀起抗肿瘤治疗新浪潮。
▌研究设计
▌基线特征
▌疗效结果
▌安全性结果
▌研究设计
▌患者基线特征、暴露情况等
▌疗效结果
▌安全性结果
DS-7300治疗难治性SCLC的I/II期研究亚组分析[4]
▌研究设计
▌基线特征
▌疗效结果
▌安全性结果
DS-7300治疗经治ES-SCLC的II期研究正在开展中[5]
参考文献:
[1] Shimizu T, Sands J, Yoh K, et al. First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01[J]. J Clin Oncol. 2023 Jun 16;JCO2300059.
[2] Goto Y, Su WC, Levy BP, et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC). ASCO 2023. 9004.
[3] Papadopoulos KP, Bruno D, Kitazono S, et al. Datopotamab Deruxtecan (Dato-DXd) + Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04. 2023 WCLC. OA05.06.
[4] Johnson M, Awad M, Koyama T, et al. Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study. 2023 WCLC. OA05.05.
[5] Rudin C, Johnson M, Girard N, et al. A Phase 2 Study of Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Previously Treated ES-SCLC. 2023 WCLC. P2.16-06.
审批编码:AD-119-202309000938
该信息仅供医疗卫生专业人士参考,仅供交流使用。